Clinical efficacy of thoracoscopic surgery combined with chemoradiotherapy in patients with N2 stage ⅢA non-small cell lung cancer
10.3969/j.issn.1006-5725.2014.19.022
- VernacularTitle:放化疗联合胸腔镜手术治疗ⅢA N2期非小细胞肺癌的临床效果
- Author:
Xiaoming ZHAI
;
Ke GU
;
Jiahua YU
;
Jianping WANG
;
Junning ZHANG
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small-cell lung;
Thoracoscopy;
Chemotherapy;
Radiotherapy
- From:
The Journal of Practical Medicine
2014;(19):3099-3101
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy of thoracoscopic surgery combined with chemorad-iotherapy in patients with N2 stage ⅢA non-small cell lung cancer (NSCLC). Methods 40 patients (study group) received thoracoscopic surgery and another 40 patients (control group) received traditional thoracotomy. Combination therapy with navelbine and cisplatin were postoperatively administered for four cycles and one cycle lasted for 3 weeks. 7 to 14 days after chemotherapy , sequential conformal radiotherapy were delivered. The one-year survival and two-year survival rates , duration of tatal treatment , and adverse reactions were compared between the two groups. Results In the study group, duration of total treatment time and time to postoperative chemotherapy were significantly shorter (χ2=9.45,P=0.002 andχ2=41.324, P=0.000), and the KPS score was significantly higher (χ2 = 15.118,P = 0.002). No significant differences were found between the two groups in bone marrow suppression,gastrointestinal reactions,and one- or two-year survival rate. Conclusions As compared with conventional surgery,post-thoracoscopic surgery sequential chemoradiotherapy for patients with N2 stage ⅢA NSCLC could achieve a better efficacy with less surgical trauma , shorter hospital stay , faster recovery , and shorter time to postoperative chemotherapy and total treatment duration;it is worth further researching and popularizing.
